Secondary analysis of the phase 2 COMRADE trial in castration-resistant prostate cancer with bone metastases (74 of 114 evaluable): adding olaparib to radium-223 made no significant difference to FACT-P quality of life or pain severity at weeks 12 or 24.
Secondary analysisn = 114
McKay et al. Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib